Whether exosome material follows an IPL session, and whether it does so the same day or later, is the practitioner’s decision, and the published record gives that decision a clear frame. IPL is described in the literature as a non-invasive light source that heats targets in the skin selectively through filters [5, 8], so a topical step afterwards meets the skin surface itself, while microneedling and fractional ablative lasers leave open channels that close over hours to a day [13, 14].
No published study located for this guide pairs vesicle material with IPL. What does exist is a set of controlled trials of ordinary skincare applied after IPL [8, 9, 10], a body of work on how large particles meet intact skin [11, 12], and the vesicle trials after channel-forming devices [2, 3], and together they show what a practice can and cannot infer.
Regulatory position
The FDA stated in its December 2019 public safety notification that there are currently no FDA-approved exosome products, and the notice remains posted as of 9 November 2026 [20]. IPL devices are classified at 21 CFR 878.4810 and reach the market through 510(k) clearance [6], and the clearance summary reviewed for this guide describes the light source with no mention of applying a topical product [7]. ExaVeyra supplies exosome material to licensed practitioners, described by its available formats, and device settings, timing and patient selection are practitioner decisions this guide does not make.
Understanding IPL as a broadband, non-ablative light source
Babilas and colleagues described IPL devices in 2010 as flashlamps fitted with bandpass filters that emit polychromatic, incoherent, high-intensity pulses of light [5]. The wavelength band, fluence, pulse duration and interval are chosen for each session, and the effect the authors described is a more or less selective thermal effect on a target in the skin [5].
Sales and colleagues described the same light in a 2022 systematic review as noncollimated, polychromatic and noncoherent [4]. Their review of 16 studies and 637 participants found that patients had a mean of 4.29 sessions, that nine of the studies had low methodological quality, and that no consensus existed on parameters [4].
A photofacial is the common name for this kind of session on the face. The term describes a use of the device, so the practice record is better served by the system, handpiece and filter actually used.
How the FDA classifies IPL devices
The FDA lists IPL under product code ONF, a powered light-based non-laser surgical instrument with a thermal effect, which the agency defines to include broad spectrum sources such as intense pulsed light [6]. The code sits under 21 CFR 878.4810, the regulation for laser surgical instruments in general and plastic surgery and dermatology, as a Class II device reviewed through the 510(k) pathway [6].
Multi-platform systems often carry IPL beside lasers in one clearance. The 510(k) summary for one such system, K250809, cleared in April 2025 under product codes GEX, ONF and ONG, gives the IPL handpiece a 400 to 1200 nm spectrum with cut-off filters from 515 to 755 nm [7].
The same summary lists the IPL handpiece beside a multi-spot Nd:YAG handpiece, a 1565 nm fractional resurfacing module and a Q-switched Nd:YAG handpiece on one platform [7]. A session recorded only as a photofacial on such a system leaves out which of those handpieces touched the skin, and that detail decides whether channels were opened at all.
An IPL session leaves the skin surface in place and its barrier briefly disturbed
IPL opens no drilled columns of the kind left by microneedles or fractional ablative lasers [13, 14]. What the post-IPL trials measured in the hours and days afterwards is how well the outer layer holds water, and Feng and colleagues described transient erythema, dryness and barrier dysfunction as possible after IPL [8].
Feng and colleagues measured that change in a 2026 split-face study of 32 women having IPL [8]. They recorded hydration and transepidermal water loss at baseline, immediately after IPL and on days 3, 7 and 28, and reported lower water loss on the side receiving a fibronectin serum than on the control side from day 3 onward, with no adverse events reported [8].
Shao and colleagues randomized each cheek of 30 participants after a single IPL session to a saccharide isomerate moisturizer or a control, applied twice a day for 7 days, and reported in 2025 greater improvement in all measured biometric parameters on the test side [9]. Wang Y and colleagues reported in a 2025 placebo-controlled trial that the test products gave lower water loss and higher stratum corneum hydration 24 hours after IPL or picosecond laser sessions, and two authors are affiliated with a subsidiary of the products’ maker [10].
The Wang Y trial also shows a design choice worth noting. Its four-week schedule began two weeks before the device session, so the products were in use on both sides of the visit, and the comparison with placebo was read at 24 hours and at later visits [10].
Hydration and transepidermal water loss are noninvasive probe measurements, and the post-IPL trials took them before the session and at fixed points afterwards [8, 9]. A practice that records the same measures has a baseline comparable to the one the published trials used.
These trials establish that a topical step after IPL is a studied practice, and that its usual endpoint is barrier recovery [8, 9, 10]. None of them used vesicle material, so they describe the surface a material meets after IPL without speaking for exosomes.
Why an intact-skin topical step differs from the post-microneedling step
The difference is the route. Microneedling and fractional ablative lasers make channels through the stratum corneum [13, 14], and a material applied while they are open meets a path into the skin; after IPL, a material meets the outer barrier itself.
Bos and Meinardi proposed in 2000 that compounds able to cross intact skin generally weigh under 500 Daltons [12]. Prow and colleagues presented data in 2011 supporting the hypothesis that particles larger than 10 nanometers are unlikely to cross the stratum corneum into viable human skin and instead collect at hair follicle openings, while significant uptake does occur once the barrier is damaged [11].
Vesicles sit far above both thresholds [19]. Neither paper studied vesicles, and no located study has measured vesicle penetration after IPL, so the scale argument sets an expectation that the literature has yet to test.
The follicle finding adds a second route to consider. Prow and colleagues reported that particles accumulated in hair follicle openings, especially after massage [11], which means the way a material is spread on the skin after IPL is itself a variable a careful record can capture.
Comparing the surface after IPL with the surface after channel-forming devices
The table sets IPL beside the two device families that most vesicle studies have used. Each row is cited in the references.
| Device family | What it does to tissue | Surface left behind | Reported closure or recovery | Located vesicle studies |
|---|---|---|---|---|
| IPL (broadband, 400 to 1200 nm) | Selective heating of targets by filtered flashlamp light [5] | Stratum corneum in place with transient barrier disturbance [8] | Barrier measures recovering over days in the post-IPL skincare trials (Feng 2026, Shao 2025, Wang Y 2025) [8, 9, 10] | None located |
| Microneedling | Mechanical microchannels through the stratum corneum [13] | Open channels [13] | Unoccluded sites recovered barrier properties within 2 hours in Gupta 2011 [13] | Park GH 2023, saline-controlled split-face, n = 28 [3] |
| Fractional ablative CO2 laser | Ablated channels in the epidermis and upper dermis [14] | Open channels [14] | 20 to 40 percent still open at 24 hours, depending on energy, in Banzhaf 2016 [14] | Kwon 2020, double-blind split-face, n = 25 [2] |
Kwon and colleagues applied an exosome gel just after each fractional CO2 session in their 2020 double-blind split-face trial [2], and Park GH and colleagues applied an exosome-containing solution with microneedling at each session in 2023 [3]. Both designs place the material on skin with open channels, which is the condition an IPL session does not create.
Timing exosomes after IPL: same day or a later visit
No located study compares a same-day topical vesicle step after IPL with a later one, so the timing question has no published answer. The post-IPL skincare trials carried their products through the days after the session and followed barrier recovery [8, 9], which gives a practice a model for what to record whichever timing it chooses.
Because IPL leaves no channel, there is no closure clock of the kind the microneedling and fractional laser studies describe [13, 14]. The considerations a practitioner weighs therefore come from the skin’s state after the session, the comfort of the patient and the handling of the material, and each can be documented.
- The skin’s condition at the end of the session, including any transient barrier disturbance of the kind Feng and colleagues measured [8]
- Whether IPL was the only device used that day, or was stacked with a channel-forming device
- The time from the end of the light session to surface application of any material
- How the material was thawed or reconstituted and how long it sat before application
Stacked sessions bring the channel question back
IPL has also been studied in the same visit as fractional lasers. Knight and Kautz reported in 2019 that 30 patients had full-face IPL with a 560 nm filter followed immediately by a 1565 nm non-ablative fractional laser at each of three sessions, with social downtime of about 1.5 days, in a study sponsored by the device maker [15].
Kim and colleagues reported a 2026 pilot in 15 adults that combined IPL with a hybrid 1470/2940 nm laser and a fractionated 1927 nm laser, in one or two combined sessions, with mild and transient symptoms [16]. When IPL shares a visit with a device that opens channels, the surface a material meets is set by that device, and the record should say which device came last.
IPL settings and skin type shape the tissue response
Lin and colleagues reviewed biomarker findings after IPL in 2024 and reported raised reactive oxygen species, p53, p16 and interleukin-6 in human or mouse skin in the studies they examined [17]. They concluded that candidate selection, optimal parameters and standardized protocols are needed [17].
El-Domyati and colleagues took biopsies from six volunteers before and after six IPL sessions in 2011 and reported no statistically significant change in collagen or elastin measures [18]. Read together with the Sales review, which found no consensus on parameters [4], the IPL literature suggests that dermal effects depend on protocol.
Skin type matters as well. Lee and colleagues reviewed noninvasive procedures for Fitzpatrick types IV to VI in 2026, concluded that these patients are at higher risk of hypo- or hyperpigmentation, and reported that IPL should be avoided in that group because of those effects [21]. Filter, fluence, pulse structure and Fitzpatrick type therefore belong in the record beside any material used.
Understanding what the evidence does not yet show
The gaps are specific, and each one is a study design the field can take up next.
- No located published study pairs exosomes, conditioned medium or any other vesicle material with an IPL session, alone or stacked; a PubMed search on 9 November 2026 returned only reviews that discuss the two topics separately.
- No study has measured how far vesicles travel into skin after IPL; the penetration thresholds from Bos 2000 and Prow 2011 come from other particles and compounds [11, 12].
- No study compares same-day application after IPL with application at a later visit.
- The post-IPL skincare trials enrolled 30 to 32 participants per split-face study, measured barrier endpoints over days to weeks, and in one case included authors affiliated with the maker of the products tested [8, 9, 10].
- The vesicle trials nearest to this question used channel-forming devices [2, 3], and Gaebe and colleagues rated the certainty of the facial vesicle evidence low or very low in a 2026 systematic review of 16 studies [1].
- Materials differ by source, isolation and concentration, so a result for one product may not transfer to another [19].
The designs already in the literature show how the first IPL study could be built. A split-face comparison of a characterized vesicle lot against its vehicle after an IPL-only session, with the barrier measures Feng and colleagues used [8] and the reporting headings of MISEV2023 [19], would answer the timing and surface questions in one protocol.
Such a study would also need to state the IPL system, filter and fluence, because the Sales review found no consensus on parameters [4]. With those fields reported, a reader could judge whether a result applies to the device in their own room.
Documenting an IPL and exosome session in practice
A practice that records the same fields the published studies report can compare its experience with the literature and answer an investigator’s or a regulator’s questions from one file. The list below follows the studies and the MISEV2023 reporting headings cited in this guide [19].
- The system and handpiece by model and 510(k) number, with filter, fluence, pulse count, pulse duration and delay, and number of passes
- Any other device used in the same visit, its settings and the order of devices
- The time from the end of the session to surface application of any material
- The material by name and class: exosomes, conditioned medium or another preparation
- The lot number, expiry, certificate of analysis and characterization panel, mapped where possible to MISEV2023 headings [19]
- The cold-chain record from receipt to use, and the time between thawing or reconstitution and application
- Fitzpatrick type, and any barrier measures the practice takes, such as hydration or transepidermal water loss
- Photographs at fixed intervals and patient-reported comfort
- Any adverse event, with the lot number, and its report to the FDA through MedWatch [20]
Questions to ask a supplier
Which source cells and isolation method produced this lot? Does the certificate of analysis report particle size, concentration, marker proteins, sterility and serological testing? Is the lot’s miRNA cargo characterized? How is the material shipped and at what temperature, and does the cold-chain record cover every leg? Which published study, if any, used the same material?
The IPL question is one of the most open in the field, and the practices that document their sessions carefully are the ones best placed to help answer it. ExaVeyra supplies exosome material to licensed practitioners, described by its available formats. It ships frozen from the manufacturing facility in every available format, every vial carries its lot number, and a certificate of analysis is generated for every lot and available on request, together with the characterization panel and cold-chain records. Every certificate reports serological testing for pathogens, and ExaVeyra’s miRNA characterization data is available on request, so the material in a practice file can be described to the standard the best studies set.
Anyone can ask the scientific team a question or apply without an NPI, and NPI verification unlocks the practitioner portal, exclusive resources and pricing, so a practice planning its first IPL documentation file can apply for a verified account today.
Educational Disclaimer: This article is for educational purposes only and does not constitute medical or legal advice. It does not identify any material, compound, device setting or protocol as safe, effective or appropriate for any patient, and it is not intended to diagnose, treat, cure, or prevent any disease. Questions about a treatment belong with the reader’s own licensed provider. Exosome material is supplied for topical aesthetic use by licensed practitioners. No exosome product is FDA-approved for any use, and ExaVeyra Sciences makes no statement about administration, route, or outcome. Compounded medications are not FDA-approved. They are prepared by a 503A compounding pharmacy licensed by the Texas State Board of Pharmacy for an individual patient against that patient’s prescription, and are available to NPI-verified licensed practitioners only, in the states where the pharmacy is licensed. Product, device and brand names mentioned are trademarks of their respective owners and are used only to identify the products discussed. Their mention is not an endorsement, and those owners have not reviewed or endorsed this article. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. Findings described are attributed to the peer-reviewed literature, trial registries and agencies cited. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.
References
- 1.Gaebe K, Lowe K, Bosnalie D, Khoury S, Villemure Poliquin N, Nichols A. Effectiveness and Safety of Extracellular Vesicle-Based Therapies for Nonsurgical Facial Rejuvenation: A Systematic Review. Facial Plast Surg Aesthet Med. 2026. Published online ahead of print. PMID 42487416. doi:10.1177/26893614261457879PRISMA systematic review with risk of bias and GRADE assessment, searches January 2000 to June 2025; 16 studies, 503 participants. Carries in this article: the authors rated the certainty of the facial vesicle evidence low or very low, with risk of bias moderate to critical. Disclosure: academic authors (Canada); no COI statement in the PubMed record.
- 2.Kwon HH, Yang SH, Lee J, Park BC, Park KY, Jung JY, et al. Combination Treatment with Human Adipose Tissue Stem Cell-derived Exosomes and Fractional CO2 Laser for Acne Scars: A 12-week Prospective, Double-blind, Randomized, Split-face Study. Acta Derm Venereol. 2020;100(18):adv00310. PMID 33073298. PMC9309822. doi:10.2340/00015555-3666Prospective, double-blind, randomized split-face trial over 12 weeks; adults with atrophic acne scars (Korea); n = 25. Carries in this article: an exosome gel applied just after each fractional CO2 session, which is a channel-forming device, as the contrast with a surface-only IPL session. Disclosure: the exosome and control gels were manufactured and provided by the exosome manufacturer; the authors declared no conflicts.
- 3.Park GH, Kwon HH, Seok J, Yang SH, Lee J, Park BC, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study. J Cosmet Dermatol. 2023;22(12):3418-3426. PMID 37377400. doi:10.1111/jocd.15872Prospective, randomized, split-face comparative study over 12 weeks; three microneedling sessions three weeks apart; exosome-containing solution on one side and saline on the other (Korea); n = 28. Carries in this article: the microneedling design that most published vesicle studies follow, with the material applied at the same visit as the channels are made. Disclosure: National Research Foundation of Korea grants listed in the record; no COI statement in the PubMed record.
- 4.Sales AFS, Pandolfo IL, de Almeida Cruz M, Parisi JR, Garcia LA, Martignago CCS, et al. Intense Pulsed Light on skin rejuvenation: a systematic review. Arch Dermatol Res. 2022;314(9):823-838. PMID 34609598. doi:10.1007/s00403-021-02283-2PRISMA systematic review registered in PROSPERO (CRD42021237817); 16 studies, 637 participants, Fitzpatrick I to IV, a mean of 4.29 sessions. Carries in this article: the description of IPL as noncollimated, polychromatic and noncoherent light, the finding that nine of the studies had low methodological quality, and the authors’ conclusion that there is no consensus on parameters. Disclosure: academic authors (Brazil); no COI statement in the PubMed record.
- 5.Babilas P, Schreml S, Szeimies RM, Landthaler M. Intense pulsed light (IPL): a review. Lasers Surg Med. 2010;42(2):93-104. PMID 20166155. doi:10.1002/lsm.20877Narrative review of IPL physics and practical use, drawn from a database search and the authors’ experience. Carries in this article: the authors described IPL devices as flashlamps with bandpass filters emitting polychromatic, incoherent, high-intensity pulsed light, working by a more or less selective thermal effect on a target. Included as an older landmark in addition to the recent sources. Disclosure: academic authors (Regensburg); no COI statement in the PubMed record.
- 6.U.S. Food and Drug Administration. Product Classification: ONF, Powered Light Based Non-Laser Surgical Instrument With Thermal Effect. 21 CFR 878.4810, Class II, 510(k). Verified 9 November 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?id=ONF; regulation text at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=878.4810Agency product classification record (CDRH). Carries in this article: the FDA defines product code ONF as a light-based non-laser device with a thermal effect, including broad spectrum sources such as IPL, classified under 21 CFR 878.4810 as Class II and reviewed through the 510(k) pathway.
- 7.U.S. Food and Drug Administration. 510(k) Premarket Notification K250809, Stellar M22, Lumenis Be Ltd. Cleared April 16, 2025. Product codes GEX, ONF, ONG; 21 CFR 878.4810. Verified 9 November 2026. https://www.accessdata.fda.gov/cdrh_docs/pdf25/K250809.pdfFDA clearance letter and 510(k) summary for a multi-platform system with an IPL handpiece. Carries in this article: the IPL module emits a 400 to 1200 nm spectrum with cut-off filters from 515 to 755 nm, the system is cleared under 21 CFR 878.4810 with product codes including ONF, and the summary describes the light source and its indications with no mention of applying a topical product. Disclosure: a manufacturer submission.
- 8.Feng H, Ge L, Shi G, Yu S, Wang X, Li X, et al. Fibronectin-Based Skin Care Regimens for Skin Recovery After Intense Pulsed Light Therapy: A Split-Face Study. Clin Cosmet Investig Dermatol. 2026;19:564788. PMID 41858601. PMC12997270. doi:10.2147/CCID.S564788Split-face study over 28 days; healthy women having IPL, a fibronectin serum on one side and a control serum on the other (China); n = 32. Carries in this article: the authors described transient barrier disturbance after IPL, measured hydration and transepidermal water loss at baseline, immediately after IPL and on days 3, 7 and 28, and reported lower water loss on the fibronectin side from day 3 with no adverse events. Disclosure: the authors reported no conflicts of interest.
- 9.Shao H, Wang L, Wang Y, Wang C, Chen L, Tang J, et al. A novel facial moisturizer containing Saccharide isomerate accelerates skin barrier restoration following intense pulsed light treatment: a randomized split-face study. J Dermatolog Treat. 2025;36(1):2585243. PMID 41211697. doi:10.1080/09546634.2025.2585243Randomized split-face study; adults with photoaged skin after a single IPL session, a test moisturizer on one randomly assigned cheek and a control on the other, applied twice a day for 7 days (China); n = 30. Carries in this article: the authors reported significantly greater improvement in all biometric parameters on the test side and no related adverse events. Disclosure: hospital authors (Tsinghua Changgung); no COI statement in the PubMed record.
- 10.Wang Y, Ning J, Zhu J, Fang X, Lee Y, Liao C, et al. Efficacy and safety of commercially available cosmetic perioperative skincare products for non-invasive energy-based device treatment: a single-centre, randomized, placebo-controlled trial. Eur J Dermatol. 2025;35(3):209-217. PMID 40742058. doi:10.1684/ejd.2025.4890Single-centre, randomized, placebo-controlled trial over four weeks, two of them before the device session, with IPL and picosecond laser arms (China). Carries in this article: the authors described energy-based sessions as impairing barrier integrity, and reported lower transepidermal water loss and higher stratum corneum hydration at 24 hours with the test products than with placebo. Disclosure: two authors are affiliated with a subsidiary of the maker of the products tested, per the PubMed affiliations.
- 11.Prow TW, Grice JE, Lin LL, Faye R, Butler M, Becker W, et al. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev. 2011;63(6):470-91. PMID 21315122. doi:10.1016/j.addr.2011.01.012Narrative review with the authors’ unpublished clinical penetration data. Carries in this article: the authors presented data supporting the hypothesis that particles larger than 10 nanometers are unlikely to cross the stratum corneum into viable human skin, collecting instead at hair follicle openings, and reported that significant uptake does occur after damage and in certain diseased skin. Disclosure: academic authors (Queensland); no COI statement in the PubMed record.
- 12.Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9(3):165-9. PMID 10839713. doi:10.1034/j.1600-0625.2000.009003165.xNarrative analysis of topical compounds and contact allergens. Carries in this article: the authors proposed that compounds able to cross intact skin generally weigh under 500 Daltons, a scale far below any vesicle. Included as an older landmark in addition to the recent sources. Disclosure: academic authors (Amsterdam); no COI statement in the PubMed record.
- 13.Gupta J, Gill HS, Andrews SN, Prausnitz MR. Kinetics of skin resealing after insertion of microneedles in human subjects. J Control Release. 2011;154(2):148-55. PMID 21640148. PMC3164267. doi:10.1016/j.jconrel.2011.05.021Human in vivo study by electrical impedance spectroscopy across microneedle geometries, with and without occlusion. Carries in this article: the authors reported that unoccluded microneedle sites recovered barrier properties within 2 hours, and occluded sites over 3 to 40 hours. Disclosure: academic authors (Georgia Institute of Technology); no COI statement in the PubMed record.
- 14.Banzhaf CA, Wind BS, Mogensen M, Meesters AA, Paasch U, Wolkerstorfer A, et al. Spatiotemporal closure of fractional laser-ablated channels imaged by optical coherence tomography and reflectance confocal microscopy. Lasers Surg Med. 2016;48(2):157-65. PMID 26266688. doi:10.1002/lsm.22386In vivo imaging study after 10,600 nm fractional CO2 on the forearm of healthy volunteers; n = 6. Carries in this article: the authors reported that 20 to 40 percent of channels, depending on energy, were still open at 24 hours, which marks the channel time course an IPL session does not create. Disclosure: academic authors; no COI statement in the PubMed record.
- 15.Knight JM, Kautz G. Sequential facial skin rejuvenation with intense pulsed light and non-ablative fractionated laser resurfacing in fitzpatrick skin type II-IV patients: A prospective multicenter analysis. Lasers Surg Med. 2019;51(2):141-149. PMID 30091207. PMC6585794. doi:10.1002/lsm.23007Prospective multicenter study, three same-day sessions 4 to 6 weeks apart, follow-up to 6 months; adults, Fitzpatrick II to IV; n = 30. Carries in this article: the full text describes IPL with a 560 nm filter followed immediately by a 1565 nm non-ablative fractional laser module on the same platform, and the authors reported social downtime of 1.5 ± 0.25 days. Disclosure: the full text states the device maker sponsored the study and both authors speak on behalf of and perform research for it (NCT02032771).
- 16.Kim C, Thota R, Nadarajan K, Barillas J, Hoopman J, Kenkel JM. A Pilot Study Combining Intense Pulsed Light, Hybrid Fractional 1470/2940-nm Laser, and Fractionated 1927-nm Laser for Diffuse Pigmentation and Actinic Changes. Aesthet Surg J Open Forum. 2026;8:ojag172. doi:10.1093/asjof/ojag172Single-center, nonrandomized prospective pilot, one or two combined sessions; adults, Fitzpatrick I to IV; n = 15. Carries in this article: IPL is now studied in the same session as fractional lasers that do open channels, and the authors reported mild, transient symptoms and no serious adverse events. Disclosure: checked against the Crossref record and abstract on 9 November 2026 (no PMID assigned yet); no vesicle material was studied.
- 17.Lin MY, Wong TW, Lin CS. Revisiting Unaddressed Safety Concerns Regarding Intense Pulsed Light Treatment: Past and Present Perspectives. Photodermatol Photoimmunol Photomed. 2024;40(6):e13005. PMID 39388538. doi:10.1111/phpp.13005Narrative review of biomarker findings after IPL in human and mouse skin. Carries in this article: the authors reported raised reactive oxygen species, p53, p16 and interleukin-6 after IPL in the studies reviewed, and called for careful candidate selection, optimal parameters and standardized protocols. Disclosure: academic authors (Taiwan); no COI statement in the PubMed record.
- 18.El-Domyati M, El-Ammawi TS, Moawad O, Medhat W, Mahoney MG, Uitto J. Intense pulsed light photorejuvenation: a histological and immunohistochemical evaluation. J Drugs Dermatol. 2011;10(11):1246-52. PMID 22052303Prospective biopsy study, six IPL sessions two weeks apart, biopsies at baseline, at the end and three months later; Fitzpatrick III to IV volunteers (Egypt); n = 6. Carries in this article: the authors reported no statistically significant change in collagen or elastin measures after IPL, a reminder that dermal effects vary by protocol. Disclosure: academic authors; no COI statement in the PubMed record.
- 19.Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al; MISEV Consortium; Théry C, Witwer KW. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. PMID 38326288. PMC10850029. doi:10.1002/jev2.12404International Society for Extracellular Vesicles reporting guideline. Carries in this article: the characterization headings a certificate of analysis can be read against (separation from non-vesicular particles, size, concentration, marker proteins and morphology). Disclosure: many consortium authors list EV company affiliations, declared in the article.
- 20.U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. December 6, 2019 (content current as of 12/06/2019; verified 9 November 2026). https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-productsAgency safety notification (CBER). Carries in this article: the statement that there are currently no FDA-approved exosome products, and the MedWatch route for adverse event reports.
- 21.Lee SS, Burgener MM, Sayyed AA, Catterall L, Koljonen JL, Ruffolo A, et al. Noninvasive Cosmetic Treatments for Fitzpatrick IV-VI: A Narrative Review of Safety and Efficacy Guidelines. Plast Reconstr Surg Glob Open. 2026;14(3):e7541. PMID 41884758. PMC13012588. doi:10.1097/GOX.0000000000007541Narrative review of PubMed literature on noninvasive procedures for Fitzpatrick skin types IV to VI (United States). Carries in this article: the authors concluded that these patients are at higher risk of hypo- or hyperpigmentation after such procedures and reported that IPL capable of resurfacing and hair removal should be avoided in that group. Disclosure: one author reported consulting for device makers and an exosome company; the other authors declared no financial interest.